---
figid: PMC6480014__ijms-20-01692-g002
figtitle: Rationale for combining immune checkpoint inhibitors with antiangiogenic
  drugs, anti-tumor immune response modulation adapted from Amin et al
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6480014
filename: ijms-20-01692-g002.jpg
figlink: /pmc/articles/PMC6480014/figure/ijms-20-01692-f002/
number: F2
caption: Rationale for combining immune checkpoint inhibitors with antiangiogenic
  drugs, anti-tumor immune response modulation adapted from Amin et al. Frontiers
  in Oncology. 2019. TCR, T cell receptor; MDSC, myeloid derived suppressor cells;
  VEGF, vascular endothelial growth factor; PD-1, programmed death 1; PD-L1, programmed
  death ligand 1; CTLA 4, cytotoxic T lymphocyte antigen 4.
papertitle: Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
reftext: Sol√®ne-Florence Kammerer-Jacquet, et al. Int J Mol Sci. 2019 Apr;20(7):1692.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8672989
figid_alias: PMC6480014__F2
figtype: Figure
redirect_from: /figures/PMC6480014__F2
ndex: e33cd78b-de95-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6480014__ijms-20-01692-g002.html
  '@type': Dataset
  description: Rationale for combining immune checkpoint inhibitors with antiangiogenic
    drugs, anti-tumor immune response modulation adapted from Amin et al. Frontiers
    in Oncology. 2019. TCR, T cell receptor; MDSC, myeloid derived suppressor cells;
    VEGF, vascular endothelial growth factor; PD-1, programmed death 1; PD-L1, programmed
    death ligand 1; CTLA 4, cytotoxic T lymphocyte antigen 4.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - CTLA4
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - DCLK1
  - ADGRL1
  - CLU
  - AKR1C4
  - GZMB
  - POLR3K
  - TCL1A
  - KDR
  - FLT1
  - FLT4
  - IDO1
  - TCR
  - Sunitinib
  - Pazopanib
  - Cabozantinib
  - ' Cytotoxic T'
  - Cytotoxic
---
